Compare · ABIO vs NNNN
ABIO vs NNNN
Side-by-side comparison of ARCA biopharma Inc. (ABIO) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABIO and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $2.33B, about 91.2x ABIO ($25.5M).
- NNNN has hit the wire 1 time in the past 4 weeks while ABIO has been quiet.
- Company
- ARCA biopharma Inc.
- Anbio Biotechnology
- Price
- $2.45-2.78%
- $15.80-13.33%
- Market cap
- $25.5M
- $2.33B
- 1M return
- -
- -39.68%
- 1Y return
- -
- +83.51%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 0
- 0
ARCA biopharma Inc.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Latest ABIO
- Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.
- Director Fairmount Funds Management Llc was granted 275,000 shares (SEC Form 4)
- ARCA biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SC 13D filed by ARCA biopharma Inc.
- New insider Fairmount Funds Management Llc claimed ownership of 2,936,922 shares (SEC Form 3)
- New insider Turtle Cameron claimed ownership of 85,233 shares (SEC Form 3)
- SEC Form 3 filed by new insider Kulkarni Samarth
- SEC Form 3 filed by new insider Dambkowski Carl
- SEC Form 3 filed by new insider Ball Kristine M
- SEC Form 3 filed by new insider Quinlan Paul T
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum